Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 510 (Sotorasib) and Digoxin Interaction Study
NCT05598281Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration (Cmax) of Digoxin Administered Alone at Day 1, Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Digoxin Administered Alone at Day 1 and 4 more. Started Nov 2019; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05598281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598281.